New Equilibrium provides a platform that learns biophysics with AI to reveal experimentally-invisible conformations of shapeshifting proteins. Its technology combines AI and biophysics to uncover opportunities for structure-based design against intrinsically disordered proteins, a class that includes many high-priority targets in cancer, neurodegeneration, and other indications. The company is led by Founder and CEO Dr. Virginia Burger; Dr. Peter Tompa chairs the Scientific Advisory Board. New Equilibrium intends to use recent funding to scale up its R&D facility, expand the team, accelerate its IDP-targeting programs, and explore strategic partnerships. The platform and programs are positioned to enable rational design against targets that have historically been elusive to conventional structure-based approaches.

Total raised

$10M

Funding rounds

1

Latest round

Seed

Latest activity

Apr 2021